CBIO
Crescent Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.88
+2.35%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- -13.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -94.0%
- EBITDA
- +74.3%
- EPS
- +59.7%
Three-year CAGR
- Revenue
- +424.9%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- +76.6%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026